Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study.
biomarkers
ductal carcinoma in situ
prospective study
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
04
10
2023
received:
20
07
2023
accepted:
12
10
2023
medline:
28
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
aheadofprint
Résumé
Observational studies have shown associations between circulating levels of various biomarkers (eg, total cholesterol [TC], low-density lipoprotein cholesterol [LDL], insulin-like growth factor-1 [IGF-1], C-reactive protein [CRP] and glycated hemoglobin-1c [HbA1c]) and the risk of invasive breast cancer (IBC). Ductal carcinoma in situ of the breast (DCIS) is a nonobligate precursor of IBC and shares several risk factors with it. However, the relationship between these biomarkers and DCIS risk remains unexplored. We studied the association between circulating levels of TC, LDL-C, high-density lipoprotein cholesterol (HDL-C), Lipoprotein (a) (Lp-(a)), IGF-1, CRP and HbA1c, with the risk of DCIS in 156801women aged 40 to 69 years and breast cancer-free at enrolment when blood samples and information on demographic and health-related factors were collected. Incident cases of DCIS were ascertained during the follow-up via linkage to the UK cancer registries Multivariable-adjusted Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of interest. In all, 969 DCIS incident cases were diagnosed during 11.4 years of follow-up. Total cholesterol was inversely associated with the risk of DCIS (HR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Breast Cancer Research Foundation
ID : BCRF-23-140
Informations de copyright
© 2023 UICC.
Références
Grimm LJ, Rahbar H, Abdelmalak M, Hall AH, Ryser MD. Ductal carcinoma in situ: state-of-the-art review. Radiology. 2022;302(2):246-255.
Chootipongchaivat S, van Ravesteyn NT, Li X, et al. Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Res. 2020;22(1):53.
Peila R, Arthur R, Rohan TE. Risk factors for ductal carcinoma in situ of the breast in the UK Biobank cohort study. Cancer Epidemiol. 2020;64:101648.
Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017;18(8):e457-e471.
Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(1):307-314.
Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218-1240.
Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. Am J Cardiol. 2010;106(1):56-61.
Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289(2):187-193.
Nam SY, Marcus C. Growth hormone and adipocyte function in obesity. Horm Res. 2000;53(Suppl 1):87-97.
Alikhani N, Ferguson RD, Novosyadlyy R, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene. 2013;32(8):961-967.
Pussinen PJ, Karten B, Wintersperger A, et al. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem J. 2000;349(Pt 2):559-566.
Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat. 2010;122(3):661-670.
Brady NJ, Chuntova P, Schwertfeger KL. Macrophages: regulators of the inflammatory microenvironment during mammary gland development and breast cancer. Mediat Inflamm. 2016;2016:4549676.
Prueitt RL, Boersma BJ, Howe TM, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer. 2007;120(4):796-805.
Mathews EH, Visagie MH, Meyer AA, Joubert AM, Mathews GE. In vitro quantification: long-term effect of glucose deprivation on various cancer cell lines. Nutrition. 2020;74:110748.
Touvier M, Fassier P, His M, et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Br J Nutr. 2015;114(3):347-357.
Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37(2):234-244.
Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause (New York, NY). 2006;13(4):643-650.
Peila R, Rohan TE. Diabetes, glycated hemoglobin, and risk of cancer in the UK Biobank study. Cancer Epidemiol Biomarkers Prev. 2020;29(6):1107-1119.
Murphy N, Knuppel A, Papadimitriou N, et al. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women. Ann Oncol. 2020;31(5):641-649.
Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol. 2010;171(5):624-632.
Garcia-Estevez L, Moreno-Bueno G. Updating the role of obesity and cholesterol in breast cancer. Breast Cancer Res. 2019;21(1):35.
Wilkens TL, Ziegler Z, Aru V, et al. 1-2 drinks per day affect lipoprotein composition after 3 weeks-results from a cross-over pilot intervention trial in healthy adults using nuclear magnetic resonance-measured lipoproteins and apolipoproteins. Nutrients. 2022;14(23):1-19.
Nelson ER, Chang CY, McDonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab. 2014;25(12):649-655.
His M, Zelek L, Deschasaux M, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol. 2014;29(2):119-132.
Kitahara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592-1598.
Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Cardiometabolic factors and breast cancer risk in U.S. black women. Breast Cancer Res Treat. 2012;134(3):1247-1256.
Ni H, Liu H, Gao R. Serum lipids and breast cancer risk: a meta-analysis of prospective cohort studies. PLoS One. 2015;10(11):e0142669.
Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause (New York, NY). 2013;20(12):1301-1309.
Nowak C, Ärnlöv J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk. Nat Commun. 2018;9(1):3957.
Zhao P, Xia N, Zhang H, Deng T. The metabolic syndrome is a risk factor for breast cancer: a systematic review and meta-analysis. Obes Facts. 2020;13(4):384-396.
Cruz P, Torres C, Ramírez ME, Epuñán MJ, Valladares LE, Sierralta WD. Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med. 2010;1(3):531-536.
de Medina P, Paillasse MR, Segala G, et al. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nat Commun. 2013;4:1840.
Lu CW, Lo YH, Chen CH, et al. VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis. Cancer Lett. 2017;388:130-138.
Johnson KE, Siewert KM, Klarin D, et al. The relationship between circulating lipids and breast cancer risk: a Mendelian randomization study. PLoS Med. 2020;17(9):e1003302.
Lippi G, Franchini M, Salvagno GL, Guidi GC. Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev. 2007;33(5):427-436.
Wang X, Wang Y, Wang M, Chen X, Cui W, Chen X. The association between serum lipid levels and histological type of breast cancer. Eur J Med Res. 2022;27(1):154.
Joshu CE, Prizment AE, Dluzniewski PJ, et al. Glycated hemoglobin and cancer incidence and mortality in the atherosclerosis in communities (ARIC) study, 1990-2006. Int J Cancer. 2012;131(7):1667-1677.
Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg-Olofsson K, Gudbjörnsdottir S. HbA1C and cancer risk in patients with type 2 diabetes-a nationwide population-based prospective cohort study in Sweden. PLoS One. 2012;7(6):e38784.
Travier N, Jeffreys M, Brewer N, et al. Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study. Ann Oncol. 2007;18(8):1414-1419.
Lin J, Ridker PM, Rifai N, et al. A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. Cancer Res. 2006;66(5):2869-2875.
Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856-862.
Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat. 1998;47(3):209-217.
Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530-542.
Knuppel A, Fensom GK, Watts EL, et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK Biobank. Cancer Res. 2020;80(18):4014-4021.
Tang SN, Zuber V, Tsilidis KK. Identifying and ranking causal biochemical biomarkers for breast cancer: a Mendelian randomisation study. BMC Med. 2022;20(1):457.
Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155-170.
Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med. 2022;20(1):301.